These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 29434858)

  • 21. miR-125b-5p inhibits breast cancer cell proliferation, migration and invasion by targeting KIAA1522.
    Li Y; Wang Y; Fan H; Zhang Z; Li N
    Biochem Biophys Res Commun; 2018 Sep; 504(1):277-282. PubMed ID: 30177391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of HAX-1 by miR-125a reverses cisplatin resistance in laryngeal cancer stem cells.
    Liu J; Tang Q; Li S; Yang X
    Oncotarget; 2016 Dec; 7(52):86446-86456. PubMed ID: 27880721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. miR-125b regulates side population in breast cancer and confers a chemoresistant phenotype.
    Wang HJ; Guo YQ; Tan G; Dong L; Cheng L; Li KJ; Wang ZY; Luo HF
    J Cell Biochem; 2013 Oct; 114(10):2248-57. PubMed ID: 23606360
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MicroRNA-125b attenuates epithelial-mesenchymal transitions and targets stem-like liver cancer cells through small mothers against decapentaplegic 2 and 4.
    Zhou JN; Zeng Q; Wang HY; Zhang B; Li ST; Nan X; Cao N; Fu CJ; Yan XL; Jia YL; Wang JX; Zhao AH; Li ZW; Li YH; Xie XY; Zhang XM; Dong Y; Xu YC; He LJ; Yue W; Pei XT
    Hepatology; 2015 Sep; 62(3):801-15. PubMed ID: 25953743
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [MiR-433 reverses chemoresistance to docetaxel by targeting Notch1 in breast cancer cells].
    Hu X; Huang P; Wang J; He W; Zhao P; Yao G; Ye C
    Nan Fang Yi Ke Da Xue Xue Bao; 2018 Jul; 38(7):888-894. PubMed ID: 33168512
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ATP-dependent activity and mitochondrial localization of drug efflux pumps in doxorubicin-resistant breast cancer cells.
    Dartier J; Lemaitre E; Chourpa I; Goupille C; Servais S; Chevalier S; Mahéo K; Dumas JF
    Biochim Biophys Acta Gen Subj; 2017 May; 1861(5 Pt A):1075-1084. PubMed ID: 28214549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overexpression of microRNA-125b sensitizes human hepatocellular carcinoma cells to 5-fluorouracil through inhibition of glycolysis by targeting hexokinase II.
    Jiang JX; Gao S; Pan YZ; Yu C; Sun CY
    Mol Med Rep; 2014 Aug; 10(2):995-1002. PubMed ID: 24865963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MiR-181b promotes chemoresistance in breast cancer by regulating Bim expression.
    Zheng Y; Lv X; Wang X; Wang B; Shao X; Huang Y; Shi L; Chen Z; Huang J; Huang P
    Oncol Rep; 2016 Feb; 35(2):683-90. PubMed ID: 26572075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. miR-125b modulates megakaryocyte maturation by targeting the cell-cycle inhibitor p19
    Qu M; Fang F; Zou X; Zeng Q; Fan Z; Chen L; Yue W; Xie X; Pei X
    Cell Death Dis; 2016 Oct; 7(10):e2430. PubMed ID: 27763644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LncRNA-DANCR Interferes With miR-125b-5p/HK2 Axis to Desensitize Colon Cancer Cells to Cisplatin vis Activating Anaerobic Glycolysis.
    Shi H; Li K; Feng J; Liu G; Feng Y; Zhang X
    Front Oncol; 2020; 10():1034. PubMed ID: 32766131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. miR-125b inhibited epithelial-mesenchymal transition of triple-negative breast cancer by targeting MAP2K7.
    Hong L; Pan F; Jiang H; Zhang L; Liu Y; Cai C; Hua C; Luo X; Sun J; Chen Z
    Onco Targets Ther; 2016; 9():2639-48. PubMed ID: 27226726
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating microRNA-125b and microRNA-130a expression profiles predict chemoresistance to R-CHOP in diffuse large B-cell lymphoma patients.
    Yuan WX; Gui YX; Na WN; Chao J; Yang X
    Oncol Lett; 2016 Jan; 11(1):423-432. PubMed ID: 26870228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA-33a-5p overexpression sensitizes triple-negative breast cancer to doxorubicin by inhibiting eIF5A2 and epithelial-mesenchymal transition.
    Guan X; Gu S; Yuan M; Zheng X; Wu J
    Oncol Lett; 2019 Dec; 18(6):5986-5994. PubMed ID: 31788073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of miR-23a attenuates doxorubicin-induced mitochondria-dependent cardiomyocyte apoptosis by targeting the PGC-1α/Drp1 pathway.
    Du J; Hang P; Pan Y; Feng B; Zheng Y; Chen T; Zhao L; Du Z
    Toxicol Appl Pharmacol; 2019 Apr; 369():73-81. PubMed ID: 30831132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MicroRNA regulates human vitamin D receptor.
    Mohri T; Nakajima M; Takagi S; Komagata S; Yokoi T
    Int J Cancer; 2009 Sep; 125(6):1328-33. PubMed ID: 19437538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Camptothecin induces apoptosis in cancer cells via microRNA-125b-mediated mitochondrial pathways.
    Zeng CW; Zhang XJ; Lin KY; Ye H; Feng SY; Zhang H; Chen YQ
    Mol Pharmacol; 2012 Apr; 81(4):578-86. PubMed ID: 22252650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. miR-125b lowers sensitivity to apoptosis following mitotic arrest: Implications for breast cancer therapy.
    Matuszyk J; Klopotowska D
    J Cell Physiol; 2020 Oct; 235(10):6335-6344. PubMed ID: 32052874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MicroRNA-125b inhibits cell proliferation and induces cell apoptosis in esophageal squamous cell carcinoma by targeting BMF.
    Fan YX; Bian XH; Qian PD; Chen ZZ; Wen J; Luo YH; Yan PW; Zhang Q
    Oncol Rep; 2018 Jul; 40(1):61-72. PubMed ID: 29749531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MiR-142-3p enhances chemosensitivity of breast cancer cells and inhibits autophagy by targeting HMGB1.
    Liang L; Fu J; Wang S; Cen H; Zhang L; Mandukhail SR; Du L; Wu Q; Zhang P; Yu X
    Acta Pharm Sin B; 2020 Jun; 10(6):1036-1046. PubMed ID: 32642410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Doxorubicin-induced loss of DNA topoisomerase II and DNMT1- dependent suppression of MiR-125b induces chemoresistance in ALK-positive cells.
    Congras A; Caillet N; Torossian N; Quelen C; Daugrois C; Brousset P; Lamant L; Meggetto F; Hoareau-Aveilla C
    Oncotarget; 2018 Mar; 9(18):14539-14551. PubMed ID: 29581862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.